<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010123</url>
  </required_header>
  <id_info>
    <org_study_id>PMCF-001</org_study_id>
    <nct_id>NCT04010123</nct_id>
  </id_info>
  <brief_title>Post-Market Clinical Follow Up of Rotarex®S Catheter</brief_title>
  <official_title>Post-Market Clinical Follow Up of Rotarex®S Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Straub Medical AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Straub Medical AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-Market Clinical Follow Up of the Rotarex®S Catheter
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multi-center, non-randomized, multiple cohorts, observational, post market
      clinical follow-up study of the Rotarex®S Catheter to evaluate the safety, technical
      performance and medical efficacy of the Rotarex®S Catheter as a stand-alone and adjunctive
      therapy for the treatment of acute, subacute and chronic occlusions and sub-occlusions of
      arteries outside the cardiopulmonary, coronary and cerebral circulations, in accordance with
      Rotarex®S Catheter intended use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from major adverse events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as clinically driven target lesion revascularization (TLR), any death and any unplanned major amputation of the index limb.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(MAE) Major adverse events Rate</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Defined as clinically driven target lesion revascularization (TLR), any death and any unplanned major amputation of the index limb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>Day 1</time_frame>
    <description>defined as the ability to cross and treat the target lesion with the Rotarex®S Catheter to achieve residual angiographic stenosis no greater than 50% directly after Rotarex®S Catheter use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Freedom of Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of Target Vessel Revascularization (TVR)</measure>
    <time_frame>1, 6, 12 and 24 Months</time_frame>
    <description>Freedom of Target Vessel Revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant Rotarex®S Catheter -related distal embolization requiring further treatment with pharmacologic or mechanical devices (except treating with intravascular nipride or nitroglycerin).</measure>
    <time_frame>From start to end of procedure</time_frame>
    <description>Rotarex®S Catheter -related distal embolization requiring further treatment with pharmacologic or mechanical devices (except treating with intravascular nipride or nitroglycerin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Rotarex®S Catheter -related perforations.</measure>
    <time_frame>From start to end of procedure</time_frame>
    <description>Rotarex®S Catheter -related perforations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Defined as clinical category improvement in the Rutherford Class at 1, 6, 12 and 24 months with reference to the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic success</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as a &gt; 0.15 improvement in ABI (ankle-brachial index) at 30 days with reference to the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency at 1, 6, 12 and 24 months.</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Defined as freedom from &gt;50% restenosis as indicated by an independently verified duplex ultrasound peak systolic velocity ratio (PSVR) &lt; 2.5 in the target vessel with no clinically driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking improvement at 1, 6, 12 and 24 months assessed by Vascu Quality of Life Questionnaire (VQ-6).</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Walking improvement assessed by Vascu Quality of Life Questionnaire (VQ-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life improvement at 1, 6, 12 and 24 months assessed by Questionnaire. (EQ5D-3L)</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Improvement of quality of life assessed by Questionnaire (EQ5D-3L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay for index procedure [days].</measure>
    <time_frame>Duration of hospital stay, up to 12 weeks</time_frame>
    <description>Number of day from admission to discharge from hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay for index procedure [days].</measure>
    <time_frame>Duration of ICU stay, up to 12 weeks</time_frame>
    <description>Number of day from admission to discharge from intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>From start to end of procedure</time_frame>
    <description>Successful revascularization of target lesion defined as ≤30% residual angiographic diameter stenosis following Rotarex®S Catheter treatment ± adjunctive treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful use of Arterio Venous-Fistula as dialysis access, defined as successful use of the fistula for dialysis on at least one occasion.</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Only for patient subject to Arterio Venous-Fistula treatment with Rotarex®S Catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients whose hemodialysis is efficient at 1, 6, 12 and 24 months without needing further treatment of the stenotic site after Rotarex®S treatment of the Arterio Venous-Fistula.</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Only for patient subject to Arterio Venous-Fistula treatment with Rotarex®S Catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(SAEs) Serious Adverse events Rate</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>SAEs as defined per ISO 14155.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related Adverse events Rate</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Procedure-related AEs as defined per ISO 14155.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(ADEs) Adverse device effects Rate</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Adverse device effects (ADEs) as defined per ISO 14155.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atherectomy/Thrombectomy</intervention_name>
    <description>Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute / Subacute / Chronic occlusions (Thrombotic / Thromboembolic / Atherothrombotic) of
        Native Arteries, Stents and Stents-grafts, Bypass grafts and AV-Fistula (Dialysis access))
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is ≥18 years old at the time of consent.

          2. Subject has provided written informed consent prior to participation in the study,
             understands the purpose of this study and agrees to comply with all protocol-specified
             examinations and follow-up appointments.

          3. Female patients of childbearing potential have negative pregnancy test ≤7 days before
             the procedure.

          4. Documented symptomatic peripheral arterial disease.

          5. Acute, subacute and chronic (sub-) occlusion, with ≥ 90% stenosis in native arteries
             and/or stents / stent grafts and/or Bypass grafts and/or AV Fistula (Dialysis access).

          6. De novo or re-occluded lesion.

          7. Vessel and/or stent diameter within treatable range as per Instruction For Use.

          8. Occlusion crossed intraluminally by a guidewire.

             For patients requiring lower limb intervention:

          9. Patient presenting with a category from 2 to 5 according to the Rutherford
             classification for chronic limb ischemia or a category from I to IIb according to the
             Rutherford classification for acute limb ischemia.

        Exclusion Criteria:

          1. Life expectancy &lt; 2 years.

          2. Pregnant or nursing a child.

          3. Contraindication, intolerance, or allergy to contrast media that, in the opinion of
             the investigator, cannot be adequately pre-medicated.

          4. Myocardial infarction within 60 days prior to index procedure.

          5. History of severe trauma and/or sepsis within 60 days prior to index procedure.

          6. Cerebrovascular accident (CVA) or Transient Ischemic Attack (TIA) within 60 days prior
             to index procedure.

          7. Evidence of intracranial or gastrointestinal bleeding or intracranial aneurysm within
             90 days prior to index procedure.

          8. Abnormal electrocardiogram or blood test results and/or any other factor that would
             increase risk by participating in the study in the opinion of the investigator.

          9. Target lesion not crossed with guidewire or extraluminal guidewire crossing (even if
             in short segments only).

         10. Additional lesion that is located &gt;3cm away from the target lesion

         11. Treatment plan of the target lesion includes laser, brachytherapy, or atherectomy
             other than the Rotarex®S Catheter.

         12. Patient is currently participating in another investigational drug or device study
             that has not reached the primary endpoint.

         13. Patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics.

         14. Patients with uncorrected bleeding disorders.

         15. Thrombophlebitis or deep vein thrombosis within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lichtenberg, Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Klinikum Hochsauerland GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torsten Böhler, Dr.</last_name>
    <phone>81 720 05 12</phone>
    <phone_ext>0041</phone_ext>
    <email>torsten.boehler@straubmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walter Mayerl, Dr.</last_name>
    <phone>81 720 05 34</phone>
    <phone_ext>0041</phone_ext>
    <email>Walter.Mayerl@straubmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angiocentrum Příbram</name>
      <address>
        <city>Příbram</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Heller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East-Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika Palmiste-Kallion, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital François-Mitterrand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romaric Loffroy, MD. PhD</last_name>
    </contact>
    <investigator>
      <last_name>Romaric Loffroy, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Hochsauerland GmbH</name>
      <address>
        <city>Arnsberg</city>
        <zip>59759</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lichtenberg, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zeller, MD. PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Friedrichshafen</name>
      <address>
        <city>Friedrichshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick de Graaf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dierk Scheinert, MD. PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bonifatius Hospital</name>
      <address>
        <city>Lingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Tessarek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jörg Tessarek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Malyar, MD. PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Radebeul</name>
      <address>
        <city>Radebeul</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Fuss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Riesa</name>
      <address>
        <city>Riesa</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Fuss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Torgau &quot;Johann Kentmann&quot;</name>
      <address>
        <city>Torgau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Maiwald, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lars Maiwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale P. Pederzoli - Casa di Cura Privata Spa</name>
      <address>
        <city>Peschiera Del Garda</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattia Mirandola, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

